What It Is
Thymosin alpha-1 is a 28-amino-acid peptide; chemically produced thymalfasin has the same amino-acid sequence. It is distinct from thymosin beta-4 and TB-500.[1][2]
Thymalfasin products have country-specific approvals outside the United States, including defined uses in Italy, India, and Hong Kong. Those authorizations apply to particular regulated products and indications and do not establish FDA approval or equivalence of a U.S. compounded or online vial.[1]
How It Is Studied
Research describes immune-modulating effects involving T cells, dendritic cells, natural-killer cells, cytokines, and toll-like-receptor signaling. These mechanisms are not a general license to say the peptide boosts immunity; a laboratory immune signal does not predict a clinical benefit or a safe effect in autoimmune disease, transplantation, infection, or cancer.[2]
What the Evidence Shows
Human studies exist across hepatitis, infection, sepsis, COVID-19, cancer, vaccine response, and other conditions, but their relevance and quality vary. A Cochrane review found the chronic-hepatitis-B evidence insufficient for firm conclusions.[3]
FDA's 2024 review concluded that subcutaneous thymosin alpha-1 free base or acetate lacked adequate effectiveness evidence for every evaluated use. Limitations included small samples, retrospective or single-arm designs, inadequate controls, outdated comparator therapy, heterogeneous populations, unclear endpoints, and concurrent treatments that prevented attribution.[1] Evidence from older therapeutic settings should not be presented as proof of benefit alongside modern standard care.
Safety and Product Quality
LiverTox describes thymalfasin as generally well tolerated and not convincingly linked to clinically apparent liver injury, but that narrow observation is not a complete safety profile.[2] FDA found no developmental, reproductive, or carcinogenicity studies adequate for the nominated substances and identified unresolved aggregation, impurity, endotoxin, formulation, and immunogenicity concerns for compounded injections.[1]
A safety record from a regulated foreign thymalfasin product cannot be transferred automatically to a different bulk substance, concentration, manufacturer, or compounded preparation.
Regulatory Status
Thymosin alpha-1 is not FDA-approved. FDA proposed not adding the free base or acetate to the 503A Bulks List in 2024 after concluding that the available evidence did not support the evaluated compounded uses and that product-quality and immunogenicity questions remained.[1][4]
The International-Approval Boundary
The accurate statement is that defined thymalfasin products have been authorized in some jurisdictions for particular indications. It is inaccurate to turn that into thymosin alpha-1 is approved without naming the country, product, indication, formulation, and regulator. It is equally inaccurate to treat an unverified U.S. research or compounded product as interchangeable with the studied pharmaceutical.[1]